

ARES ALLERGY HOLDINGS PLC

ARES ALLERGY HOLDINGS PLC PUBLISHES HALF-YEAR 2015 REPORT AND FINANCIAL STATEMENTS

London (United Kingdom), 30 September 2015 – Ares Allergy Holdings plc (the “Company”, Euronext: STAGR) announces that its consolidated interim financial statements for the six month period ended 30 June 2015 and its half-year report 2015 are now available.

These interim financial statements consolidate the Company’s results as of 30 June 2015 and incorporate revenues from Finares Holding AG and Ares Allergy Holdings, Inc. (which includes GREER Laboratories Inc.) from 12 May 2015, the date at which their shares were contributed to the Company. The interim financial statements exclude STALLERGENES SA’s revenues, which combined with the Company only on 8 September 2015.

These financial statements do not include the full results of all the entities composing the newly combined Group over the first semester. They should be read in conjunction with the unaudited pro forma financial information of the Group for the period from 1 January to 30 June 2015 and with the 2014 comparatives from 6 December 2013 (date of incorporation of the Company) to 30 June 2014, included in the half-year report 2015 and in the prospectus which received visa n° 15-466 from the *Autorité des marchés financiers* on September 3, 2015.

The Company’s consolidated interim financial statements at 30 June 2015 have been prepared in accordance with IAS 34 ‘Interim Financial Reporting’ as published by the IASB, as adopted by the European Union. They were approved by the Board of Directors on 29 September 2015.

The half-year report 2015 including the interim financial statements is available on the Company’s website (www.aresallergy.com).

ABOUT ARES ALLERGY HOLDINGS PLC

Headquartered in London (UK), Ares Allergy Holdings plc is a global company specialising in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Ares Allergy Holdings plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and STALLERGENES SAS (whose registered office is in France).

Trading information:

Name: Stallergenes Greer

ISIN: GB00BZ21RF93 1 - Ticker: STAGR

ICB classification: 4577

Market: Euronext Paris regulated market

Additional information is available at <http://www.aresallergy.com>

Contacts:**Investor and analyst relations**

Peter Bühler

Chief Financial Officer

Tel: +33 1 55 59 23 22

Email: investorrelations@aresallergyco.com

Media relations

Lise Lemonnier

Head of Global Communications

Tel: + 33 1 55 59 20 96

Email: llemonnier@stallergenes.com

Investor and Media relations agency:

UK: Robin Wrench, Brunswick Group

Email: aresallergy@brunswickgroup.com

Tel. +44 (0)20 7404 5959